{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:30:59Z","timestamp":1776684659487,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40265-016-0649-1","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T08:41:20Z","timestamp":1477039280000},"page":"1523-1528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Collagenase Clostridium Histolyticum for the Treatment of Peyronie\u2019s Disease: A \u2018Real World\u2019 Clinical Perspective"],"prefix":"10.1007","volume":"76","author":[{"given":"James","family":"Anaissie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J. G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,21]]},"reference":[{"key":"649_CR1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol."},{"key":"649_CR2","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175:2115\u20138 (discussion 2118).","journal-title":"J Urol."},{"key":"649_CR3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","volume":"10","author":"CJ Nelson","year":"2013","unstructured":"Nelson CJ, Mulhall JP. Psychological impact of Peyronie\u2019s disease: a review. J Sex Med. 2013;10:653\u201360.","journal-title":"J Sex Med."},{"key":"649_CR4","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.","journal-title":"Adv Urol."},{"key":"649_CR5","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374.","journal-title":"J Sex Med."},{"issue":"5","key":"649_CR6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0022-5347(17)67832-7","volume":"71","author":"GH Teasley","year":"1954","unstructured":"Teasley GH. Peyronie\u2019s disease; a new approach. J Urol. 1954;71(5):611\u20134.","journal-title":"J Urol."},{"key":"649_CR7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J Urol. 2002;168:621\u20135 (discussion 625\u20136).","journal-title":"J Urol."},{"key":"649_CR8","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J Urol. 2013;190:2194\u20139.","journal-title":"J Urol."},{"key":"649_CR9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1743-6109.2007.00581.x","volume":"4","author":"S Glina","year":"2007","unstructured":"Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA. The use of collagenase in the treatment of Peyronie\u2019s disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J Sex Med. 2007;4:1209\u201313.","journal-title":"J Sex Med."},{"key":"649_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","volume":"10","author":"MK Gelbard","year":"1982","unstructured":"Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie\u2019s disease experimental studies. Urol Res. 1982;10:135\u201340.","journal-title":"Urol Res."},{"key":"649_CR11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"LC Hurst","year":"2009","unstructured":"Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al. Injectable collagenase Clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med. 2009;361:968\u201379.","journal-title":"N Engl J Med."},{"key":"649_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol."},{"key":"649_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J Urol. 2013;190:627\u201334.","journal-title":"J Urol."},{"key":"649_CR14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie\u2019s disease. J Urol. 2016;195:1051\u20136.","journal-title":"J Urol."},{"issue":"2","key":"649_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bju.13396","volume":"118","author":"C Poullis","year":"2016","unstructured":"Poullis C, Shabbir M, Eardley I, Mulhall J, Minhas S. Clostridium histolyticum collagenase: is this revolutionary medical treatment for Peyronie\u2019s disease? BJU Int. 2016;118(2):186\u20139.","journal-title":"BJU Int."},{"key":"649_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jsm.12721","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Larsen SM. Surgical correction of persistent Peyronie\u2019s disease following collagenase Clostridium histolyticum treatment. J Sex Med. 2015;12:259\u201364.","journal-title":"J Sex Med."},{"key":"649_CR17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie\u2019s disease. J Sex Med. 2016;13:684\u20139.","journal-title":"J Sex Med."},{"key":"649_CR18","doi-asserted-by":"crossref","unstructured":"Cordon B, Hutchinson R, Hofer M, Broderick G, Lota Y, Morey A (eds). Superior cost effectiveness of penile plication versus intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities. Podium presentation at the American Urological Association (AUA) Annual Conferenc, 6\u201310 May 2016, San Diego, CA.","DOI":"10.1016\/j.juro.2016.02.2106"},{"issue":"4 Suppl. 1","key":"649_CR19","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1016\/j.juro.2015.02.2764","volume":"193","author":"I Goldstein","year":"2015","unstructured":"Goldstein I, Knoll D, Lipshultz L, Tursi J, Smith T, Kaufman G, et al. Changes in the effects of Peyronie\u2019s disease after treatment with collagenase Clostridium histolyticum according to men with Peyronie\u2019s disease and their female sexual partners. J Urol. 2015;193(4 Suppl. 1):e968\u20139.","journal-title":"J Urol."},{"key":"649_CR20","unstructured":"Anaissie J, Yafi F, Traore E, Sikka S, Hellstrom WJG (eds). Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie\u2019s disease. Podium presentation at the American Urological Association (AUA) Annual Conference, 6\u201310 May 2016, San Diego, CA."},{"key":"649_CR21","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jsxm.2016.02.122","volume":"13","author":"D Milam","year":"2016","unstructured":"Milam D. Positive results with collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie\u2019s disease. J Sex Med. 2016;13:S55.","journal-title":"J Sex Med."},{"key":"649_CR22","doi-asserted-by":"crossref","unstructured":"Sangkum P, Yafi FA, Kim H, et al. Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. Urology. 2015;86:647.e1\u20136.","DOI":"10.1016\/j.urology.2015.06.013"},{"key":"649_CR23","unstructured":"Anaissie J, Yafi F, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG (eds). Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease. Podium presentation at the American Urological Association (AUA) 2016 Annual Meeting, 6\u201310 May 2016, San Diego, CA."},{"issue":"8","key":"649_CR24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1358\/dot.2015.51.8.2375756","volume":"51","author":"J Anaissie","year":"2015","unstructured":"Anaissie J, Powers MK, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum for the pharmacological management of Peyronie\u2019s disease. Drugs Today (Barc). 2015;51(8):457\u201368.","journal-title":"Drugs Today (Barc)."},{"key":"649_CR25","doi-asserted-by":"crossref","unstructured":"Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie\u2019s disease. J Urol. 1985;134(2):280\u20133.","DOI":"10.1016\/S0022-5347(17)47123-0"},{"key":"649_CR26","doi-asserted-by":"crossref","unstructured":"Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J Urol. 1993;149(1):56\u20138.","DOI":"10.1016\/S0022-5347(17)35998-0"},{"key":"649_CR27","doi-asserted-by":"crossref","unstructured":"Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180\u20137.","DOI":"10.1111\/j.1743-6109.2007.00651.x"},{"key":"649_CR28","doi-asserted-by":"crossref","unstructured":"Gelbard M, Lipshultz L, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268-74.","DOI":"10.1016\/j.juro.2012.01.032"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0649-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0649-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0649-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T22:37:47Z","timestamp":1657492667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0649-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0649-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}